Anti-proliferative effects of paroxetine alone or in combination with sorafenib in HepG2 cells
Abstract Hepatocellular carcinoma (HCC) is a common cause of cancer-related death. Sorafenib is the first approved drug for the treatment of advanced HCC. Depression is frequent in cancer patients. Moreover, sorafenib might exert depression as an adverse drug reaction and paroxetine, a selective ser...
Saved in:
Main Authors: | Yaprak Donmez Cakil (Author), Zeynep Gunes Ozunal (Author), Damla Gokceoglu Kayali (Author), Ranan Gulhan Aktas (Author), Esra Saglam (Author) |
---|---|
Format: | Book |
Published: |
Universidade de São Paulo,
2023-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Dihydroartemisinin enhances the inhibitory effect of sorafenib on HepG2 cells by inducing ferroptosis and inhibiting energy metabolism
by: Zhao Cui, et al.
Published: (2022) -
Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma
by: Xiaolong Tang, et al.
Published: (2018) -
Transcriptome Analyses of the Anti-Proliferative Effects of 20(S)-Ginsenoside Rh2 on HepG2 Cells
by: Ji Zhang, et al.
Published: (2019) -
The Effect of Alpha Mangostin on Epithelial-Mesenchymal Transition on Human Hepatocellular Carcinoma HepG2 Cells Surviving Sorafenib via TGF-β/Smad Pathways
by: Syarinta Adenina, et al.
Published: (2020) -
Design, synthesis and biological evaluation of novel diosgenin-benzoic acid mustard hybrids with potential anti-proliferative activities in human hepatoma HepG2 cells
by: Jinling Zhang, et al.
Published: (2022)